Clinical characteristics predict benefits from eptifibatide therapy during coronary stenting: insights from the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy (ESPRIT) trial (Q46951736)
Jump to navigation
Jump to search
scientific article published on 26 January 2006
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Clinical characteristics predict benefits from eptifibatide therapy during coronary stenting: insights from the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy (ESPRIT) trial |
scientific article published on 26 January 2006 |
Statements
1 reference
Clinical characteristics predict benefits from eptifibatide therapy during coronary stenting: insights from the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy (ESPRIT) trial (English)
1 reference
Karen S Pieper
1 reference
Joseph A Puma
1 reference
Lesan T Banko
1 reference
Terrence J Sacchi
1 reference
J Conor O'Shea
1 reference
Jean Pierre Dery
1 reference
James E Tcheng
1 reference
26 January 2006
1 reference
47
1 reference
715-718
1 reference
4
1 reference
Identifiers
1 reference
1 reference